Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Nov 2;14(1):26452.
doi: 10.1038/s41598-024-72704-5.

Blood-based MASH diagnostic in candidates for bariatric surgery using mid-infrared spectroscopy: a European multicenter prospective study

Maëna Le Corvec  1 , Marwin A Farrugia  2 , Eric Nguyen-Khac  3 , Jean-Marc Régimbeau  4   5 , Abdennaceur Dharhri  4   5 , Denis Chatelain  6 , Litavan Khamphommala  7 , Anne-Lise Gautier  8 , Nathalie Le Berre  9 , Sébastien Frey  10 , Jean-Pierre Bronowicki  11 , Laurent Brunaud  12 , Chloé Maréchal  11 , Marie-Cécile Blanchet  13 , Vincent Frering  13 , Jean Delwaide  14 , Laurent Kohnen  15 , Alexandre Haumann  15 , Philippe Delvenne  16 , Marine Sarfati-Lebreton  17 , Hugues Tariel  1 , Jérôme Bernard  1 , Alexis Toullec  1 , Jérôme Boursier  17 , Pierre Bedossa  18 , Philippe Gual  19 , Rodolphe Anty  20 , Antonio Iannelli  2
Affiliations
Multicenter Study

Blood-based MASH diagnostic in candidates for bariatric surgery using mid-infrared spectroscopy: a European multicenter prospective study

Maëna Le Corvec et al. Sci Rep. .

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is common in individuals with obesity. Sexual dimorphism is present in MASLD. A noninvasive test to diagnose the severity of the disease, in particular the presence of Metabolic dysfunction-associated steatohepatitis (MASH), is lacking. This European multicenter prospective study uses a blood test based on mid-infrared (MIR) metabolic fingerprinting of individuals with severe or morbid obesity to diagnose MASH. Three hundred eighty-two individuals with severe or morbid obesity undergoing bariatric surgery were enrolled prospectively. Liver biopsies were obtained during surgery and assessed centrally. An algorithm was defined to calculate a score from the recorded MIR spectrum and to establish a diagnostic threshold to classify patients with MASH. Among the women (n = 217), MASH was diagnosed in 14.3% of cases. For women, the performance in terms of AUC were 0.83 and 0.82 in the calibration and validation groups, respectively. For a threshold of 0.1817, sensitivities were 86% and 70%, specificities were 81% and 75%, PPV were 43% and 32%, NPV were 97% and 94% and ACC were 82% and 74% for the calibration and validation groups, respectively. For men (n = 78; MASH: 33.3%), the performance of the spectral model was poor. The metabolic fingerprint obtained by MIR spectroscopy can rule out MASH in women with severe or morbid obesity. Its value in men needs new studies.Trial registration: ClinicalTrials.gov identifier: ClinicalTrials.gov identifier: NCT03978247 (04/06/2019).

Keywords: Infrared spectroscopy; MAFLD; MASH; Noninvasive test; Severe obesity.

PubMed Disclaimer

Conflict of interest statement

Maëna Le Corvec and Alexis Toullec were DIAFIR employees; Jérôme Bernard was the DIAFIR General Manager for Healthcare; Hugues Tariel is the DIAFIR Chief Executive Officer. All the remaining authors declare no conflict of interest.

Figures

Fig. 1
Fig. 1
Participant flow chart specifying the number of individuals excluded from the clinical study.
Fig. 2
Fig. 2
Overview of the main steps of the study leading to the construction of the MASH diagnostic models from mid-infrared spectra and biological data.
See this image and copyright information in PMC

References

    1. Rinella, M. E. et al. A multi–society Delphi consensus statement on new fatty liver disease nomenclature. J. Hepatol.10.1016/j.jhep.2023.06.003 (2023). - PubMed
    1. Riazi, K. et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol.7(9), 851–861. 10.1016/S2468-1253(22)00165-0 (2022). - PubMed
    1. Younossi, Z. M. et al. Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology64(1), 73. 10.1002/hep.28431 (2016). - PubMed
    1. Divella, R., Mazzocca, A., Daniele, A., Sabbà, C. & Paradiso, A. Obesity, nonalcoholic fatty liver disease and adipocytokines network in promotion of cancer. Int. J. Biol. Sci.15(3), 610–616. 10.7150/ijbs.29599 (2019). - PMC - PubMed
    1. Hales, C. M., Carroll, M. D., Fryar, C. D. & Ogden, C. L. Prevalence of obesity and severe obesity among adults: United States, 2017–2018. NCHS Data Brief.360, 1–8 (2020). - PubMed

Publication types

Associated data